Mvvh1987
$IMUX Stifel reinforced why I’m so bullish on the leadership. Lundgren helped build and launch Ocrevus and knows what it takes to create a blockbuster in a “crowded” MS market. Tardio knows how to position and commercialize MS therapies. Their message was clear: ~30% relapse reduction + strong MRI + differentiated safety/tolerability could make VidoCa highly competitive. December decides.
10
